Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Alpha Tau Medical Ltd. - Warrant
Andina Copper Corporation
DAQO New Energy Corp. American Depositary Shares
Energy Select Sector SPDR
Fast Retailing CO Ltd
First Trust RiverFront Dynamic Developed International ETF
Grayscale Litecoin TR Ltc
MEI Pharma, Inc. - Common Stock
Procure Disaster Recovery Strategy ETF
Salem Media Group, Inc. - Class A Common Stock
Samsara Inc. Class A Common Stock
Shuttle Pharmaceuticals Holdings, Inc. - common stock
VeriSign
Edit Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ImmunoPrecise Antibodies Ltd. - Common Stock
(NQ:
IPA
)
2.070
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Sep 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunoPrecise Antibodies Ltd. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025
December 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Earnings Scheduled For December 10, 2024
↗
December 10, 2024
Via
Benzinga
A Preview Of ImmunoPrecise Antibodies's Earnings
↗
December 09, 2024
Via
Benzinga
IPA to Present at The Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
December 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024
December 03, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
“Emerging Innovators Transforming Global Markets: IPA, CRDL, KXIN, GNS, PRSO in Sectors”
November 13, 2024
Via
AB Newswire
Topics
Electric Vehicles
$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies
November 13, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation
November 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Advances Anti-Aging Research with Mayo Clinic Study, Poised to Tap into $81 Billion Market with AI Technology
October 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Participate at the AI Driven Drug Discovery Summit USA 2024
October 21, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Celebrates Nobel Prize in Chemistry, Advances in AI-Powered Protein Design
October 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Subsidiary Signs Material Transfer Agreement with Biotheus
October 02, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Advances Therapeutic Innovation with Groundbreaking Rabbit Antibody Developments
September 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025
September 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2025 on September 16, 2024
September 09, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York
August 26, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Receives Nasdaq Notification Regarding Minimum Bid Requirements
August 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies (IPA) Reports Financial Results and Business Updates for Fourth Quarter and Full Fiscal Year 2024
July 29, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies to Reschedule Financial Results and Recent Business Highlights Report for Fourth Quarter and Fiscal Year-End 2024
July 23, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Announces Financing Agreement with Yorkville Advisors Global, LP of up to $3.0 Million Aggregate Principal Amount of Convertible Debentures
July 16, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Fiscal Year End 2024 on July 25th, 2024
July 15, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Appoints Kristin Taylor as Chief Financial Officer
June 27, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration to Develop First-In-Class AI Model for Pharmacogenomics Recommendations Using LENSai™
June 25, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
ImmunoPrecise Antibodies Ltd. Subsidiary BioStrand Receives Prestigious 2024 Impact Award for Groundbreaking LENSai™ Technology
June 12, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
BioStrand, ImmunoPrecise Antibodies’ Subsidiary, Announces Immediate Commercial Offering of Groundbreaking Software with Customizable Interface for AI-Driven Drug Discovery
June 10, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
EXCLUSIVE: ImmunoPrecise Antibodies' Subsidiary Releases Software With Customizable Interface For AI-Driven Drug Discovery
↗
June 10, 2024
ImmunoPrecise Antibodies launches BioStrand's LENSaiAPI software, enhancing AI-driven drug discovery and data integration for healthcare and pharmaceutical industries.
Via
Benzinga
IPA’s Subsidiary, BioStrand, Announces Advanced Large Language Model (LLM) for Electronic Health Records (EHR)
June 04, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
Epitope Binning Powered By LENSai TM Technology Can Analyze Over 5,000 Sequences With No Physical Materials Needed, Matches Classical Wet Lab Binning Results
April 22, 2024
Via
ACCESSWIRE
ImmunoPrecise Antibodies And InterSystems Partner To Leverage AI In Life Sciences, Transforming Patient Care With Accelerated Discovery And Delivery Of Treatments
April 12, 2024
Via
ACCESSWIRE
InterSystems and IPA’s Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications
March 28, 2024
From
ImmunoPrecise Antibodies Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
